Dandamudi Gopi, Simon Joel, Cano Oscar, Master Vivak, Koruth Jacob S, Naperkowski Angela, Kean Adam C, Schaller Robert, Ellenbogen Kenneth A, Kron Jordana, Vijayaraman Pugazhendhi
Division of Cardiology, CHI Franciscan, Tacoma, Washington, USA; Division of Cardiology, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Division of Cardiology, Indiana University School of Medicine, Indianapolis, Indiana, USA.
JACC Clin Electrophysiol. 2021 Apr;7(4):522-529. doi: 10.1016/j.jacep.2020.09.015. Epub 2020 Dec 24.
This study retrospectively assessed the safety and efficacy of permanent His bundle pacing (HBP) in patients with congenital complete heart block (CCHB).
HBP has become an accepted form of pacing in adults. Its role in CCHB is not known.
Seventeen patients with CCHB who underwent successful HBP were analyzed at 6 academic centers between 2016 and 2019. Nine patients had de novo implants, and 8 patients had previous right ventricular (RV) leads. Three RV paced patients had reduced left ventricular ejection fractions at the time of HBP. Implant/follow-up device parameters, New York Heart Association functional class, QRS duration, and left ventricular ejection fraction data were analyzed.
Patients' mean age was 27.4 ± 11.3 years, 59% were women, and mean follow-up was 385 ± 279 days. The following parameters were found to be statistically significant between implant and follow-up, respectively: impedance, 602 ± 173 Ω versus 460 ± 80 Ω (p < 0.001); and New York Heart Association functional class, 1.7 ± 0.9 versus 1.1 ± 0.3 (p = 0.014). In patients with previous RV pacing, HBP resulted in a significant decrease in QRS duration: 167.1 ± 14.3 ms versus 118.3 ± 13.9 ms (p < 0.0001). In de novo implants, HBP resulted in increases in QRS duration compared with baseline: 111.1 ± 19.4 ms versus 91.0 ± 4.8 ms (p = 0.016). Other parameters exhibited no statistically significant differences. During follow-up, 2 patients required lead revision due to elevated pacing thresholds.
HBP seems to be safe and effective, with improvement in clinical outcomes in patients with CCHB. Larger studies with longer follow-up periods are required to confirm our findings.
本研究回顾性评估了永久性希氏束起搏(HBP)在先天性完全性心脏传导阻滞(CCHB)患者中的安全性和有效性。
HBP已成为成人中一种被认可的起搏方式。其在CCHB中的作用尚不清楚。
对2016年至2019年间在6个学术中心接受成功HBP治疗的17例CCHB患者进行分析。9例患者为初次植入,8例患者曾有右心室(RV)导联。3例RV起搏患者在进行HBP时左心室射血分数降低。分析植入/随访设备参数、纽约心脏协会功能分级、QRS时限和左心室射血分数数据。
患者的平均年龄为27.4±11.3岁,59%为女性,平均随访时间为385±279天。发现以下参数在植入和随访之间分别具有统计学意义:阻抗,602±173Ω对460±80Ω(p<0.001);以及纽约心脏协会功能分级,1.7±0.9对1.1±0.3(p=0.014)。在曾有RV起搏的患者中,HBP导致QRS时限显著缩短:167.1±14.3ms对118.3±13.9ms(p<0.0001)。在初次植入患者中,与基线相比,HBP导致QRS时限增加:111.1±19.4ms对91.0±4.8ms(p=0.016)。其他参数无统计学显著差异。在随访期间,2例患者因起搏阈值升高需要进行导线修正。
HBP似乎是安全有效的,可改善CCHB患者的临床结局。需要进行更大规模、更长随访期的研究来证实我们的发现。